Completion and toxicity of induction chemotherapy for metastatic testicular cancer: An updated evaluation of Japanese patients

Japanese Journal of Clinical Oncology

Volumn 36, Issue 7, 2006, Pages 425-431

  Kawai, Koji ^a   Ando, Satoshi ^a   Hinotsu, Shiro ^a   Oikawa, Takehiro ^a   Sekido, Noritoshi ^a   Miyanaga, Naoto ^a   Shimazui, Toru ^a   Akaza, Hideyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

BEP; IGCCCG classification; Testicular cancer; Toxicity

Indexed keywords

ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BLEOMYCIN; CISPLATIN; ETOPOSIDE; IFOSFAMIDE; METHYLPREDNISOLONE; METOCLOPRAMIDE; PACLITAXEL; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG FATALITY; DRUG MEGADOSE; ELECTROLYTE DISTURBANCE; FEBRILE NEUTROPENIA; GASTROINTESTINAL TOXICITY; HUMAN; HYPOCALCEMIA; HYPOCHLOREMIA; HYPONATREMIA; HYPOXEMIA; HYPOXIA; JAPAN; LEUKOPENIA; LIVER TOXICITY; LUNG FIBROSIS; LUNG INFILTRATE; MALE; MEDICAL RECORD REVIEW; METASTASIS POTENTIAL; NEPHROTOXICITY; OVERALL SURVIVAL; PNEUMONIA; SALVAGE THERAPY; SCORING SYSTEM; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; TESTIS CANCER; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING; UNIVERSITY HOSPITAL;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; BONE MARROW; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; GERMINOMA; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HUMANS; LEUKOPENIA; MALE; MIDDLE AGED; PROGNOSIS; SEROTONIN ANTAGONISTS; SURVIVAL RATE; TESTICULAR NEOPLASMS; THROMBOCYTOPENIA;

EID: 33748115490     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyl053     Document Type: Article

References (28)

1. Einhorn LH, Williams SD, Troner M, Birch R, Greco FA. The role of maintenance therapy in disseminated testicular cancer. N Engl J Med 1981;305:727-31.
2. Williams SD, Birch R, Einhorn LH, Irwin L, Greco FA, Loehrer PJ. Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 1987;316:1435-40.
3. Nichols CR, Catalano PJ, Crawford ED, Vogelzang NJ, Einhorn LH, Loehrer PJ. Randomized comparison of cisplatin and etoposide and either bleomycin or ifosfamide in treatment of advanced disseminated germ cell tumors: An Eastern Cooperative Oncology Group, Southwest Oncology Group, and Cancer and Leukemia Group B Study. J Clin Oncol 1998;16:1287-93.
4. Nichols CR, Williams SD, Loehrer PJ, Greco FA, Crawford ED, Weetlaufer J, et al. Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: A Southeastern Cancer Study Group and Southwest Oncology Group protocol. J Clin Oncol 1991;9:1163-72.
5. Husband DJ, Green JA. POMB/ACE chemotherapy in non-seminomatous germ cell tumours: Outcome and importance of dose intensity. Eur J Cancer 1992;28:86-91.
6. Miyanaga N, Akaza H, Hattori K, Takeshima H, Koiso K. The importance of dose intensity in chemotherapy of advanced testicular cancer. Urol Int 1995;54:220-5.
7. Schmoll HJ, Souchon R, Krege S, Albers P, Beyer J, Kollmannsberger C, et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004;15:1377-99.
8. Gerl A, Clemm C, Schmeller N, Hartenstein R, Lamerz R, Wilmanns W. Advances in the management of metastatic non-seminomatous germ cell tumours during the cisplatin era: A single-institution experience. Br J Cancer 1996;74:1280-5.
9. Pentheroudakis G, de Bono JS, Kaye SB, Simpson A, Paul J, Brown I, et al. Improved prognosis of patients with intermediate- and poor-risk nonseminomatous germ cell tumors by optimizing combined treatment. BJU Int 2003;92:36-12.
10. Murakami M, Hara I, Miyake H, Yamada Y, Kawabata G, Kamidono S. Advances in the management of non-seminomatous germ cell tumors during the cisplatin era: A single-institution experience. Int J Urol 2004;11:768-73.
11. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997;15:594-603.
12. Bosl GJ, Geller NL, Bajorin D, Leitner SP, Yagoda A, Gobey RB, et al. A randomized trial of etoposide + cisplatin versus vinblastine + bleomycin + cisplatin + cyclophosphamide + dactinomycin in patients with good-prognosis germ cell tumors. J Clin Oncol 1988;6:1231-8.
13. Motzer RJ, Sheinfeld J, Mazumdar M, Bains M, Mariani T, Bacik J, et al. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer. J Clin Oncol 2000;18:2413-8.
14. Kawai K, Miyazaki J, Tsukamoto S, Hinotsu S, Hattori K, Shimazui T, et al. Paclitaxel, ifosfamide and cisplatin regimen is feasible for Japanese patients with advanced germ cell cancer. Jpn J Clin Oncol 2003;33:127-31.
15. Motzer RJ, Mazumdar M, Bajorin DF, Bosl GJ, Lyn P, Vlamis V. High-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in first-line therapy for patients with poor-risk germ cell tumors. J Clin Oncol. 1997;15:2546-52.
16. Miyazaki J, Miyanaga N, Kawai K, Shimazui T, Takeshima H, Akaza H. High-dose chemotherapy with peripheral blood stem cell transplantation for advanced testicular cancer. Int J Urol 2000;7:258-62.
17. McCaffrey JA, Mazumdar M, Bajorin DF, Bosl GJ, Vlamis V, Motzer RJ. Ifosfamide- and cisplatin-containing chemotherapy as first-line salvage therapy in germ cell tumors: Response and survival. J Clin Oncol 1997;15:2559-63.
18. Dinakara P, Blumenthal WS, Johnston RF, Kauffman LA, Solnick PB. The effect of anemia on pulmonary diffusing capacity with derivation of a correction equation. Am Rev Respir Dis 1970;102:965-9.
19. SAS Institute Inc. IMP Statistics and Graphic Guide, Cary, NC, USA, 2000.
20. Fossa SD, Kaye SB, Mead GM, Cullen M, de Wit R, Bodrogi I, et al. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. European Organization for Research and Treatment of Cancer, Genito-Urinary Group, and the Medical Research Council Testicular Cancer Working Party, Cambridge, United Kingdom. J Clin Oncol 1998;16:716-24.
21. Harding MJ, Paul J, Gillis CR, Kaye SB. Management of malignant teratoma: Does referral to a specialist unit matter. Lancet 1993; 341:999-1002.
22. Collette L, Sylvester RL, Stenning SP, Fossa SD, Mead GM, de Wit R, et al. Impact of the treating institution on survival of patients with 'poor-prognosis' metastatic nonseminoma. J Natl Cancer Inst 1999;91:839-46.
23. Sharma R, Tobin P, Clarke SJ. Management of chemotherapy-induced nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 2005;6:93-102.
24. Loehrer PJ Sr, Johnson D, Elson P, Einhorn LH, Trump D. Importance of bleomycin in favorable-prognosis disseminated germ cell tumors: An Eastern Cooperative Oncology Group trial. J Clin Oncol 1995;13:470-6.
25. Simpson AB, Paul J, Graham J, Kaye SB. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: A review of patients with germ cell tumours. Br J Cancer 1998;78:1061-6.
26. Sleijfer S. Bleomycin-induced pneumonitis. Chest 2001;120:617-24.
27. Kawai K, Hinotsu S, Tomobe M, Akaza H. Serum creatinine level during chemotherapy for testicular cancer as a possible predictor of bleomycin-induced pulmonary toxicity. Jpn J Clin Oncol. 1998;28:546-50.
28. Sleijfer S, van der Mark TW, Schraffordt Koops H, Mulder NH. Decrease in pulmonary function during bleomycin-containing combination chemotherapy for testicular cancer: Not only a bleomycin effect. Br J Cancer 1995;71:120-3.